|
|
|
Insider
Information: |
Afeyan Noubar |
Relationship: |
Director, 10% Owner |
City: |
Lexington |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
20 |
|
Direct
Shares |
7,797,941 |
|
Indirect Shares
|
116,914,718 |
|
|
Direct
Value |
$20,668,772 |
|
|
Indirect Value
|
$84,459,470 |
|
|
Total
Shares |
124,712,659 |
|
|
Total
Value |
$105,128,243 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
10
|
0
|
Stock
price went up :
|
3
|
0
|
Stock
price went down : |
7
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
-22.5%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Color Kinetics Inc |
CLRK |
Director |
2005-10-03 |
83,062 |
2005-10-03 |
12,000 |
Premium* |
|
Antigenics Inc |
AGEN |
Director |
2006-12-14 |
0 |
2006-12-14 |
0 |
Premium* |
|
Helicos Biosciences Corp |
HLCSQ |
Director, 10% Owner |
2009-09-18 |
0 |
2009-09-18 |
12,192,640 |
Premium* |
|
Receptos, Inc. |
RCPT |
10% Owner |
2013-11-18 |
1,693,551 |
|
0 |
Premium* |
|
DNIB Upwind Inc |
BIND |
Director, 10% Owner |
2013-09-25 |
0 |
2013-09-25 |
1,562,616 |
Premium* |
|
Bg Medicine, Inc. |
BGMD |
Director, 10% Owner |
2015-12-09 |
0 |
2015-12-09 |
1,286,274 |
Premium* |
|
Editas Medicine, Inc. |
EDIT |
10% Owner |
2016-02-08 |
3,964,256 |
2016-02-08 |
991,060 |
Premium* |
|
Selecta Biosciences Inc |
SELB |
10% Owner |
2016-06-27 |
0 |
2016-06-27 |
1,651,862 |
Premium* |
|
Kaleido Biosciences, Inc. |
KLDO |
10% Owner |
|
0 |
2021-02-08 |
14,907,627 |
Premium* |
|
Transmedics Group, Inc. |
TMDX |
10% Owner |
|
0 |
2019-10-29 |
120,595 |
Premium* |
|
Seres Therapeutics, Inc. |
MCRB |
10% Owner |
2019-06-18 |
15,141 |
2022-07-05 |
17,617,352 |
Premium* |
|
Moderna, Inc. |
MRNA |
|
2024-04-24 |
2,041,931 |
2024-04-24 |
9,666,038 |
Premium* |
|
Axcella Health Inc. |
AXLA |
10% Owner |
2020-05-18 |
0 |
2022-10-13 |
8,850,296 |
Premium* |
|
Evelo Biosciences Inc |
EVLO |
|
2020-06-29 |
0 |
2023-07-11 |
4,977,588 |
Premium* |
|
Codiak Biosciences, Inc. |
CDAK |
10% Owner |
|
0 |
2022-09-15 |
1,674,869 |
Premium* |
|
Foghorn Therapeutics Inc. |
FHTX |
10% Owner |
2020-10-27 |
0 |
2020-10-27 |
1,851,801 |
Premium* |
|
Sigilon Therapeutics, Inc. |
SGTX |
10% Owner |
2020-12-08 |
0 |
2023-08-11 |
0 |
Premium* |
|
Sana Biotechnology, Inc. |
SANA |
10% Owner |
2021-02-08 |
0 |
2023-09-13 |
581,695 |
Premium* |
|
Rubius Therapeutics, Inc. |
RUBY |
Director, 10% Owner |
2021-03-19 |
0 |
2021-03-19 |
17,253,519 |
Premium* |
|
Omega Therapeutics, Inc. |
OMGA |
Director, 10% Owner |
2021-08-03 |
0 |
2023-02-27 |
21,716,886 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
MRNA |
Moderna, Inc. |
|
|
2024-04-24 |
4 |
AS |
$107.16 |
$1,624,836 |
D/D |
(15,000) |
2,041,931 |
0 |
- |
|
MRNA |
Moderna, Inc. |
|
|
2024-04-17 |
4 |
AS |
$103.10 |
$1,550,703 |
D/D |
(15,000) |
2,056,931 |
0 |
- |
|
MRNA |
Moderna, Inc. |
|
|
2024-04-10 |
4 |
AS |
$106.59 |
$1,606,865 |
D/D |
(15,000) |
2,071,931 |
0 |
- |
|
MRNA |
Moderna, Inc. |
|
|
2024-04-03 |
4 |
AS |
$97.47 |
$1,525,268 |
D/D |
(15,000) |
2,086,931 |
0 |
- |
|
MRNA |
Moderna, Inc. |
|
|
2024-03-27 |
4 |
AS |
$105.73 |
$1,635,864 |
D/D |
(15,000) |
2,101,931 |
0 |
- |
|
MRNA |
Moderna, Inc. |
|
|
2024-03-20 |
4 |
AS |
$101.05 |
$1,535,820 |
D/D |
(15,000) |
2,116,931 |
0 |
- |
|
MRNA |
Moderna, Inc. |
|
|
2024-03-13 |
4 |
AS |
$106.60 |
$1,628,031 |
D/D |
(15,000) |
2,131,931 |
0 |
- |
|
MRNA |
Moderna, Inc. |
|
|
2023-10-25 |
4 |
AS |
$76.73 |
$769,854 |
D/D |
(10,000) |
2,156,931 |
0 |
- |
|
MRNA |
Moderna, Inc. |
|
|
2023-10-11 |
4 |
AS |
$102.88 |
$1,549,441 |
D/D |
(15,000) |
2,166,931 |
0 |
- |
|
MRNA |
Moderna, Inc. |
|
|
2023-10-04 |
4 |
AS |
$100.02 |
$1,540,845 |
D/D |
(15,000) |
2,181,931 |
0 |
- |
|
MRNA |
Moderna, Inc. |
|
|
2023-09-27 |
4 |
AS |
$98.46 |
$989,646 |
D/D |
(10,000) |
2,196,931 |
0 |
- |
|
MRNA |
Moderna, Inc. |
|
|
2023-09-20 |
4 |
AS |
$103.87 |
$1,571,090 |
D/D |
(15,000) |
2,206,931 |
0 |
- |
|
MRNA |
Moderna, Inc. |
Director |
|
2023-09-13 |
4 |
AS |
$108.21 |
$1,645,522 |
D/D |
(15,000) |
2,221,931 |
0 |
- |
|
SANA |
Sana Biotechnology, Inc. |
10% Owner |
|
2023-09-13 |
4 |
D |
$0.00 |
$0 |
I/I |
(11,781,275) |
0 |
0 |
- |
|
MRNA |
Moderna, Inc. |
|
|
2023-09-06 |
4 |
AS |
$107.27 |
$1,614,094 |
D/D |
(15,000) |
1,982,209 |
0 |
- |
|
MRNA |
Moderna, Inc. |
|
|
2023-08-23 |
4 |
AS |
$112.61 |
$1,732,613 |
D/D |
(15,000) |
2,012,209 |
0 |
- |
|
MRNA |
Moderna, Inc. |
|
|
2023-08-16 |
4 |
AS |
$95.70 |
$975,614 |
D/D |
(10,000) |
2,027,209 |
0 |
- |
|
SGTX |
Sigilon Therapeutics, Inc... |
10% Owner |
|
2023-08-11 |
4 |
D |
$14.92 |
$11,901,982 |
I/I |
(797,720) |
0 |
0 |
- |
|
MRNA |
Moderna, Inc. |
|
|
2023-08-02 |
4 |
AS |
$110.59 |
$1,664,876 |
D/D |
(15,000) |
2,037,209 |
0 |
- |
|
MRNA |
Moderna, Inc. |
|
|
2023-07-26 |
4 |
AS |
$119.61 |
$1,806,229 |
D/D |
(15,000) |
2,052,209 |
0 |
- |
|
MRNA |
Moderna, Inc. |
|
|
2023-07-19 |
4 |
AS |
$124.14 |
$1,882,152 |
D/D |
(15,000) |
2,067,209 |
0 |
- |
|
MRNA |
Moderna, Inc. |
|
|
2023-07-12 |
4 |
AS |
$124.59 |
$1,887,081 |
D/D |
(15,000) |
2,082,209 |
0 |
- |
|
EVLO |
Evelo Biosciences Inc |
|
|
2023-07-11 |
4 |
B |
$2.31 |
$12,499,999 |
I/I |
5,411,255 |
3,931,685 |
0.01 |
% |
|
MRNA |
Moderna, Inc. |
Director |
|
2023-07-05 |
4 |
AS |
$123.46 |
$1,870,933 |
D/D |
(15,000) |
2,097,209 |
0 |
- |
|
MRNA |
Moderna, Inc. |
|
|
2023-06-28 |
4 |
AS |
$119.84 |
$1,823,160 |
D/D |
(15,000) |
2,112,209 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|